LY2940680 + lansoprazole

This combination consists of **taladegib** (LY2940680), a small molecule oral inhibitor of the Hedgehog pathway by antagonizing the Smoothened (SMO) receptor, and **lansoprazole**, an FDA-approved proton pump inhibitor used primarily for acid-related gastrointestinal diseases. Taladegib acts as an anti-cancer agent by inhibiting abnormal Hedgehog pathway activation found in various tumors, resulting in decreased proliferation of these cancer cells. Lansoprazole acts by irreversibly inhibiting the H+,K+-ATPase (proton pump) in the gastric parietal cells, thereby reducing gastric acid secretion. Although lansoprazole is sometimes studied for possible antitumor roles (via inhibition of signaling and cell cycle/proliferation pathways), there is no published evidence supporting any clinical or preclinical co-administration of taladegib (LY2940680) with lansoprazole; no dedicated studies or combination drugs exist specifically for LY2940680 + lansoprazole[1][2][5].

Brand names

taladegib

Other names

taladegib + lansoprazole